- €21.76m
- €14.00m
- €4.34m
Brief: NanoRepro FY Profit After Taxes At EUR 29.7 Mln
Brief: Nanorepro Announces Talks With Viromed Group On Integration Of Individual Business Units Terminated For The Time Being
Brief: NanoRepro Completes Comparative Study, Says Its Tests Detect Omicron
Brief: NanoRepro - Change In Forecast 2021 And Outlook 2022 With Dividend
Brief: Nanorepro - New Supervisory Board Member Will Be Appointed By Court
Brief: Nanorepro Receives Order From Viromed Group For 41 Million Corona Antigen Rapid Tests
Brief: NanoRepro Due Diligence On Viromed Group Expected To Be Completed On 22 December 2021
Brief: Nanorepro And Viromed Medical Sign Distribution Agreement With Austrian Partner
Brief: NanoRepro And Viromed Expand Partnership
Brief: NanoRepro H1 EBITDA Up At EUR 34,7 Mln
Brief: Nanorepro Reviews Possible Integration Of Three Business Areas Of Viromed Group
Brief: Nanorepro FY Loss After Taxes Turns To Profit Of EUR 1.7 Million
Brief: Nanorepro Extends Contract With CEO Lisa Jüngst
Brief: Nanorepro Expects 2021 Sales Of EUR 250-400 Mln
Brief: Nanorepro Expects 2021 EBITDA Between EUR 60 Mln And EUR 100 Mln
Brief: NanoRepro Concludes Cash Capital Increase
Brief: Nanorepro Receives Special Approval For SARS-CoV-2 Antigen Rapid Test
Retail investors' darling stock NanoRepro lures short sellers after 4,000% gain
NanoRepro: +130% in 5 days after Covid tests order win